Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Group 1 - The core point of the news is that Yuyuan Pharmaceutical has experienced a continuous decline in stock price, dropping 19.23% over the past seven days, with a current price of 21.93 yuan per share and a market capitalization of 9.869 billion yuan [1] - Yuyuan Pharmaceutical focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular drugs (55.67%), anti-infection drugs (20.88%), and diabetes medications (4.85%) [1] - The company's main products include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, and Metformin sustained-release tablets, which have substantial revenue contributions and growth potential [1] Group 2 - Huafu Fund has a significant holding in Yuyuan Pharmaceutical, with its Huafu Health and Entertainment Flexible Allocation Mixed A fund holding 520,000 shares, representing 6.13% of the fund's net value [2] - The fund has incurred a floating loss of approximately 271.44 thousand yuan during the seven-day decline, with a current year loss of 1.6% and a one-year return of 21.04% [2] - The fund manager, Liao Qingyang, has been in position for 4 years and 87 days, with the fund's total asset size at 838 million yuan [3]

Core Viewpoint - Yuyuan Pharmaceutical's stock has experienced a significant decline, dropping 5.15% on February 2, with a total market value of 10.355 billion yuan and a cumulative drop of 10.64% over the past five days [1] Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. is located in Beijing and was established on August 14, 2001, with its listing date on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - Key products contributing to revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] Group 2: Revenue Composition - The revenue composition of Yuyuan Pharmaceutical is as follows: - Cardiovascular drugs: 55.67% - Anti-infection drugs: 20.88% - Raw materials: 8.73% - Digestive system drugs: 6.87% - Diabetes medications: 4.85% - Others: 2.62% - Supplementary: 0.36% - Technical services: 0.02% [1] Group 3: Shareholder Information - E Fund's healthcare mixed fund (110023) is among the top ten circulating shareholders of Yuyuan Pharmaceutical, having increased its holdings by 2.17% to 9.7665 million shares [2] - The fund has incurred a floating loss of approximately 12.2081 million yuan today and a total floating loss of 28.2252 million yuan over the past five days [2] Group 4: Fund Performance - The fund manager of E Fund's healthcare mixed fund is Yang Zhenshao, who has a tenure of 9 years and 169 days, with a total asset scale of 7.952 billion yuan [3] - The fund has achieved a best return of 201.37% and a worst return of -19.69% during Yang's tenure [3]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -280 million to -235 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Financial Performance - The company anticipates a net profit loss for 2025, contrasting with the previous year's statutory disclosure data [1] - The adjustment in pricing and sales strategy for the product "Ginkgo Biloba Extract Injection" at the end of 2024 is expected to have a substantial phased impact on the company's revenue and profit [1] Strategic Adjustments - The company is committed to a long-term development strategy, continuously adjusting and improving its operational strategies to enhance efficiency [1] - Efforts are being made to optimize sales strategies and maintain the stability of core sales channels, thereby continuously strengthening the company's core competitiveness and investment value [1] Research and Development - During the reporting period, the company maintained a high proportion of investment in research and development, with R&D expenses increasing year-on-year [1] - The high level of R&D investment has had a certain impact on the company's net profit [1]

Core Viewpoint - Yuyuan Pharmaceutical is forecasting a net loss attributable to shareholders of the parent company for 2025, ranging from 235 million to 280 million yuan, indicating a decline compared to the previous year [1] Financial Performance - The expected net loss, excluding non-recurring gains and losses, is projected to be between 260 million and 305 million yuan [1] - The anticipated financial downturn is attributed to adjustments in pricing and sales strategies for the product "Ginkgo Leaf Extract Injection" at the end of 2024 [1] R&D Expenses - The increase in research and development expenses year-on-year is expected to have a significant impact on net profit [1]

Core Viewpoint - Yuyuan Pharmaceutical Group Co., Ltd. expects a net profit attributable to shareholders of the parent company to be between -280 million to -235 million yuan for the year 2025, indicating a loss compared to the same period last year [1] Financial Performance - The company anticipates a significant decline in revenue and profit due to adjustments in pricing and sales strategy for its product "Ginkgo Biloba Extract Injection" at the end of 2024 [1] - The high proportion of R&D investment has impacted the company's net profit, with R&D expenses increasing year-on-year [1] Strategic Initiatives - The company remains committed to its long-term development strategy, continuously adjusting and improving its operational strategies to enhance efficiency [1] - Yuyuan Pharmaceutical is focused on maintaining the stability of its core sales channels and strengthening its core competitiveness and investment value [1] - The company places a strong emphasis on R&D innovation as a strategic priority and is actively promoting new drug development projects [1]

悦康药业集团股份有限公司 2026 年第一次临时股东会会议资料 悦康药业集团股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 2 月 | | | 悦康药业集团股份有限公司 2026 年第一次临时股东会会议资料 悦康药业集团股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《公司法》《证券法》《上市公司股东会规则》以及《悦康 药业集团股份有限公司章程》（以下简称"《公司章程》"）的相关规定，认真做 好召开股东会的各项工作，特制定本须知： 一、为保证股东会的严肃性和正常秩序，切实维护股东的合法权益，除出席 会议的股东及股东代表、董事、公司高级管理人员、公司聘任律师及中介机构外， 公司有权依法拒绝其他人员入场。 二、请出席会议的股东及股东代表在会议召开前 20 分钟到达会议现场办理 签到手续。大会工作人员将对出席会议者的身份进行必要的核对工作，请被核对 者给予配合。 三、股东及股东代表参加股东会依法享有发言权、质询权、表决权等权利。 如股东及股东代表欲在本次股东会上发言，可在签到时先向大会工作人员进行登 记。会 ...

证券代码：688658 证券简称：悦康药业 公告编号：2026-003 悦康药业集团股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1.经财务部门初步测算，悦康药业集团股份有限公司（以下简称"公司"）预 计 2025 年年度实现归属于母公司所有者的净利润为-28,000.00 万元到-23,500.00 万元，与上年同期（法定披露数据）相比，将出现亏损。 2.预计 2025 年年度实现归属于母公司所有者扣除非经常性损益后的净利润 为-30,500.00 万元到-26,000.00 万元。 （三）公司本次业绩预告情况未经注册会计师审计。 二、上年同期业绩情况 （一）2024 年度，利润总额为：15,235.76 万元 归属于母公司所有者的净利润：12,371.70 万元 （二）公司坚定将研发创新置于战略核心地位，持续积极推动新药研发项目。 报告期内，公司 ...

Core Viewpoint - The company expects a significant net loss for the fiscal year 2025, with projected losses ranging from 280 million to 235 million yuan, compared to a profit of 124 million yuan in the same period last year [1] Financial Performance - The anticipated net profit attributable to the parent company is projected to be between -280 million and -235 million yuan for 2025, a stark contrast to the previous year's profit of 124 million yuan [1] - The expected non-recurring net profit is forecasted to be between -305 million and -260 million yuan, down from 111 million yuan in the prior year [1] Factors Influencing Performance - The primary reason for the expected losses is attributed to adjustments in pricing and sales strategies for the "Ginkgo Biloba Extract Injection" at the end of 2024, which is anticipated to have a significant impact on revenue and profit [1] - Additionally, the company has experienced an increase in research and development expenses compared to the previous year [1]

Core Viewpoint - Yuekang Pharmaceutical Group Co., Ltd. has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a significant step in its "A+H" dual-platform listing strategy, which aims to address its financial challenges and support R&D innovation [1][3]. Group 1: Company Overview - Yuekang Pharmaceutical, listed on the STAR Market, is transitioning to a dual listing in Hong Kong to create an international financing platform [1][3]. - The company has faced declining performance, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6][7]. Group 2: Financial Challenges - The company's core product, Ginkgo Biloba Extract Injection, has seen a price reduction of approximately 53% due to regulatory scrutiny, leading to significant revenue loss and a quarterly loss of 86.01 million yuan in Q4 2024 [6][7]. - The reliance on a single product has weakened the company's risk resilience, exposing vulnerabilities in its product pipeline [7]. Group 3: Strategic Initiatives - The funds raised from the H-share listing are intended for R&D innovation and operational capital, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual listing structure is expected to enhance liquidity and provide a valuation anchor based on the existing A-share market [10]. Group 4: Market Sentiment and Risks - Investors are cautious, weighing the potential for recovery against ongoing risks, including high sales costs and governance concerns stemming from the controlling shareholder's legal issues [9][11]. - The market perceives the recent price adjustments as a potential turning point, suggesting that the worst may be over, but uncertainties regarding profitability recovery remain [10][11]. Group 5: IPO Details - The IPO timeline is pending, with details such as the offering price and allocation mechanisms yet to be announced [13]. - The company plans to establish a green shoe mechanism to stabilize pricing, allowing underwriters to exercise an over-allotment option of up to 15% of the initial offering size [13].